Positive results from Anoro Ellipta vs Seretide and Advair Diskus in patients in COPD

14 March 2014

UK pharma giant GlaxoSmithKline (LSE: GSK) and Theravance (Nasdaq: THRX) today announced positive results from three Phase III studies with their combination chronic obstructive pulmonary disease (COPD).

Two studies comparing the efficacy and safety of the combination anticholinergic/long-acting beta2-adrenergic agonist, Anoro Ellipta (umeclidinium/vilanterol, UMEC/VI) with inhaled corticosteroid/long-acting beta2-adrenergic agonist combination, Advair Diskus (fluticasone propionate/salmeterol FSC 250/50) and the third comparing the efficacy and safety of Anoro Ellipta with Seretide DiskusFSC 500/50 in patients with COPD and no history of moderate to severe COPD exacerbations in the last year.

In each of the studies UMEC/VI achieved a statistically-significant improvement in lung function, measured as weighted mean forced expiratory volume in one second (wm FEV1) over 0-24 hours at the end of the 12 week study (day 84), compared to either dose of FSC.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK